NASDAQ:MNTA - Momenta Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$22.30 -0.45 (-1.98 %)
(As of 06/21/2018 02:21 AM ET)
Previous Close$22.75
Today's Range$22.25 - $22.95
52-Week Range$11.85 - $24.90
Volume363,500 shs
Average Volume776,831 shs
Market Capitalization$1.75 billion
P/E Ratio-18.58
Dividend YieldN/A
Beta1.65
Momenta Pharmaceuticals logoMomenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Receive MNTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MNTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNTA
CUSIP60877T10
Phone617-491-9700

Debt

Debt-to-Equity RatioN/A
Current Ratio9.80
Quick Ratio9.80

Price-To-Earnings

Trailing P/E Ratio-18.58
Forward P/E Ratio-11.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$138.88 million
Price / Sales12.46
Cash FlowN/A
Price / CashN/A
Book Value$4.90 per share
Price / Book4.55

Profitability

EPS (Most Recent Fiscal Year)($1.20)
Net Income$-88,090,000.00
Net Margins-88.77%
Return on Equity-28.56%
Return on Assets-21.66%

Miscellaneous

Employees279
Outstanding Shares77,590,000

Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) released its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.19. The biotechnology company earned $4.85 million during the quarter, compared to analysts' expectations of $15.63 million. Momenta Pharmaceuticals had a negative net margin of 88.77% and a negative return on equity of 28.56%. Momenta Pharmaceuticals's revenue for the quarter was down 81.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.46) earnings per share. View Momenta Pharmaceuticals' Earnings History.

When is Momenta Pharmaceuticals' next earnings date?

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Momenta Pharmaceuticals.

What price target have analysts set for MNTA?

8 Wall Street analysts have issued 12-month price objectives for Momenta Pharmaceuticals' stock. Their forecasts range from $6.00 to $24.00. On average, they expect Momenta Pharmaceuticals' share price to reach $15.6250 in the next year. View Analyst Ratings for Momenta Pharmaceuticals.

Who are some of Momenta Pharmaceuticals' key competitors?

Who are Momenta Pharmaceuticals' key executives?

Momenta Pharmaceuticals' management team includes the folowing people:
  • Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 58)
  • Dr. Ganesh Venkataraman Kaundinya Ph.D., Co-Founder, COO, Chief Scientific Officer & Sr. VP (Age 51)
  • Mr. Scott M. Storer, Sr. VP, CFO & Principal Accounting Officer
  • Mr. Bruce A. Leicher J.D., Sr. VP, Gen. Counsel and Corp. Sec. (Age 62)
  • Dr. Young T. Kwon Ph.D., Sr. VP of Corp. Devel. & Strategy

Has Momenta Pharmaceuticals been receiving favorable news coverage?

Media coverage about MNTA stock has been trending somewhat positive on Thursday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a media sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.91 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Momenta Pharmaceuticals' major shareholders?

Momenta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.89%), Palo Alto Investors LP (2.36%), Fiera Capital Corp (1.41%), Dimensional Fund Advisors LP (1.32%), Northern Trust Corp (1.19%) and JPMorgan Chase & Co. (0.88%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, James M Roach, Richard P Shea, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.

Which institutional investors are selling Momenta Pharmaceuticals stock?

MNTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Fiera Capital Corp, Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc., Oppenheimer Asset Management Inc., American International Group Inc. and Wells Fargo & Company MN. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Scott M Storer and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals.

Which institutional investors are buying Momenta Pharmaceuticals stock?

MNTA stock was bought by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Eventide Asset Management LLC, Rock Springs Capital Management LP, BlackRock Inc., UBS Group AG, American Century Companies Inc., Mackay Shields LLC and Prudential Financial Inc.. View Insider Buying and Selling for Momenta Pharmaceuticals.

How do I buy shares of Momenta Pharmaceuticals?

Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Momenta Pharmaceuticals' stock price today?

One share of MNTA stock can currently be purchased for approximately $22.30.

How big of a company is Momenta Pharmaceuticals?

Momenta Pharmaceuticals has a market capitalization of $1.75 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe.

How can I contact Momenta Pharmaceuticals?

Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]


MarketBeat Community Rating for Momenta Pharmaceuticals (MNTA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  398 (Vote Outperform)
Underperform Votes:  369 (Vote Underperform)
Total Votes:  767
MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe MNTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.